Nabriva Therapeutics

Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.

Earnings data Q1 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the commercialization and development of novel anti-infective agents to treat infections. The company was founded in October 2005 and is headquartered in Dublin, Ireland.

CHICAGO--(BUSINESS WIRE)--Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization of generic injectables, fertility, biologic, and branded products, today announced it has acquired North America rights to CONTEPO™ (fosfomycin for injection) from Nabriva Therapeutics. CONTEPO™ is a novel, intravenous (IV), broad spectrum antibiotic with demonstrated activity against most multi-drug resistant (.

Meitheal Pharmaceuticals Expands Specialty Biopharmaceuticals Portfolio with Acquisition of CONTEPO™ (Fosfomycin for Injection) from Nabriva Therapeutics

Bed Bath & Beyond

iBio

Redfin

Rocket Companies, Inc.

Shift Technologies

Virgin Galactic

Peruse the Internet for investment guidance and you're likely to hear the adage that you shouldn't consider stocks to sell when faced with volatility. Rather, you should buy up assets and securities when there's blood on the streets.

7 Stocks to Sell as Banks Melt Down

-Company To Focus on Preserving Cash to Fund Orderly Wind Down of Operations-

Nabriva Therapeutics Provides Corporate Update

Nabriva (NBRV) posts positive top-line data from the phase I study evaluating oral and intravenous Xenleta (lefamulin) in adult patients with cystic fibrosis. Shares down.

Nabriva (NBRV) Posts Positive Data From Cystic Fibrosis Study

Shares of Nabriva Therapeutics Plc NBRV, were up 13.8% in premarket trading on Monday after the company said in a news release it had positive data from a Phase 1 clinical trial assessing its antibiotic as a treatment for cystic fibrosis. The drug, Xenleta, is approved to treat community-acquired bacterial pneumonia.

Nabriva's stock is up after sharing antibiotic news

- PK Data and Safety Profile Consistent with Previous Studies in Healthy Subjects –

Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis

Nabriva Therapeutics plc (NASDAQ:NBRV ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Daniel Dolan - CFO Theodore Schroeder - CEO Conference Call Participants Carl Byrnes - Northland Capital Markets Ed Arce - H.C. Wainwright Operator Welcome to the Nabriva Therapeutics Third Quarter 2022 Financial Results Call and Corporate Update.

Nabriva Therapeutics plc (NBRV) Q3 2022 Earnings Call Transcript

- Shifted Focus to SIVEXTRO to Enable Cost Cutting -

Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate Update

DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its third quarter financial results along with recent company highlights after the close of the U.S. financial markets on Thursday, November 10, 2022. Nabriva's management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights.

Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022

Source: iQoncept / Shutterstock Nabriva Therapeutics (NASDAQ: NBRV ) stock caught the attention of traders on Friday after shares surged in price this morning. However, not all is as it seems.

What Is Going on With Nabriva Therapeutics (NBRV) Stock Today?

HeartBeam

Mullen Automotive

Here's what you need to know about trading penny stocks on September 16th The post Buying Penny Stocks Today? What You Need to Know  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Buying Penny Stocks Today? What You Need to Know

Nabriva Therapeutics (NBRV) announces it will effect a 1-for-25 reverse stock split. These are the details.

Nabriva Therapeutics (NBRV) Stock: 1-For-25 Reverse Stock Split Announced

DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 15, 2022 (GLOBE NEWSWIRE) --  Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will effect a 1-for-25 reverse stock split of its outstanding ordinary shares, which will be effective for trading purposes on the Nasdaq Capital Market as of the commencement of trading on September 16, 2022.

Nabriva Therapeutics Announces Date of 1-for-25 Reverse Stock Split

Nabriva Therapeutics AG (NBRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Nabriva Therapeutics AG (NBRV) Rating Upgrade to Buy

DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer at Nabriva, will provide a company overview and business update at the H.C. Wainwright 24th Annual Global Investment Conference. Management will also host investor meetings September 12-14, 2022.

Nabriva Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

- Topline Data Expected First Quarter 2023 - - Topline Data Expected First Quarter 2023 -

Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis

Nabriva Therapeutics plc (NASDAQ:NBRV ) Q2 2022 Results Conference Call August 3, 2022 4:30 PM ET Company Participants Dan Dolan - CFO Ted Schroeder - CEO Conference Call Participants Carl Byrnes - Northland Capital Markets Thomas Yip - HCW Operator Good morning, and welcome to the Nabriva Therapeutics Second Quarter 2022 Financial Results Conference Call. [Operator Instructions] Please note that this event is being recorded today.

Nabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q2 2022 Results - Earnings Call Transcript

-Net Product Sales of $8.7M Grew 25% versus Q2 2021-

Nabriva Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

DUBLIN, Ireland and FORT WASHINGTON, Pa., July 20, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its second quarter financial results along with recent company highlights after the close of the U.S. financial markets on Wednesday, August 3, 2022. Nabriva's management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights.

Nabriva Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Highlights on August 3, 2022

DUBLIN, Ireland and FORT WASHINGTON, Pa., July 18, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has entered into an exclusive Distribution Agreement with Er-Kim, a leading partner for biotech companies in international markets, for the oral and intravenous formulations of XENLETA® (lefamulin).

Nabriva Therapeutics Expands XENLETA® (lefamulin) Presence with Exclusive Agreement with Er-Kim Pharmaceuticals

DUBLIN, Ireland, May 13, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer at Nabriva, will provide a company overview and business update at the H.C. Wainwright Global Investment Conference. The presentation will be available on-demand beginning on Tuesday, May 24 at 7:00 am ET. Management will also host investor meetings May 24-26, 2022.

Nabriva Therapeutics to Present at the H.C. Wainwright Global Investment Conference

Nabriva Therapeutics plc (NASDAQ:NBRV ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Dan Dolan - Chief Financial Officer Ted Schroeder - Chief Executive Officer Christine Guico-Pabia - Chief Medical Officer Conference Call Participants Carl Byrnes - Northland Capital Markets Thomas Yip - HC Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the Nabriva Therapeutics First Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode.

Nabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q1 2022 Results - Earnings Call Transcript

-SIVEXTRO Distribution and Promotion Agreement with Merck Formally Extended Through at Least 2026-

Nabriva Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update

DUBLIN, Ireland and FORT WASHINGTON, Pa., May 05, 2022 (GLOBE NEWSWIRE) --  Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it agreed to an extension of its exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA (“Merck”), known as MSD outside the United States and Canada, to promote and distribute SIVEXTRO® (tedizolid phosphate) in the United States through December 31, 2026. SIVEXTRO is an oxazolidinone-class antibacterial indicated in adults and pediatric patients 12 years of age and older for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by certain susceptible Gram-positive microorganisms.

Nabriva Extends Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S. Through the End of 2026

DUBLIN, Ireland and FORT WASHINGTON, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its first quarter financial results along with recent company highlights after the close of the U.S. financial markets on Thursday, May 5, 2022. Nabriva's management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights.

News for Nabriva Therapeutics Stock (NBRV)